Arkowitz David
- SEC CIK
- 0001296999
No open-market purchases or sales filed in the past year.
Current role at each company
- IBIO iBio, Inc.Directoras of Nov 24, 2025
- KA Kineta, Inc.Directoras of Jul 2, 2025
- MCRB Seres Therapeutics, Inc.Chief Financial Officeras of Feb 16, 2024
- FSTX F-star Therapeutics, Inc.Directoras of Mar 9, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Arkowitz David as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
IBIO iBio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Arkowitz DavidDirector | PPurchase | +18.4K | $2.72 | +$50.0K | New position18.4K after |
MCRB Seres Therapeutics, Inc.
Chief Financial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2024 (view filing) | Feb 16 | Same day | Arkowitz DavidChief Financial Officer | SSale | −3.94K | $1.08 | −$4.25K | −2.1%182.4K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 30 | 1 day | Arkowitz DavidChief Financial Officer | SSale | −4.07K | $1.35 | −$5.49K | −2.3%175.8K after | 10b5-1 |